SCHEMBL1373501

SCHEMBL1373501

N[C@@H](CCC(=O)OC=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 2/20 0.54
GSR P00390 2/20 0.54
GRM8 O00222 2/20 0.54
GRM6 O15303 2/20 0.54
GRM7 Q14831 2/20 0.54
GRM4 Q14833 2/20 0.54
GRIN2D O15399 1/20 0.54
GRIN3B O60391 1/20 0.54
CYP1A2 P05177 1/20 0.54
GRIK1 P39086 1/20 0.54
GRM5 P41594 1/20 0.54
GRIA1 P42261 1/20 0.54
GRIA2 P42262 1/20 0.54
GRIA3 P42263 1/20 0.54
SLC1A3 P43003 1/20 0.54
SLC1A2 P43004 1/20 0.54
GRIA4 P48058 1/20 0.54
GRIN1 Q05586 1/20 0.54
GRIN2A Q12879 1/20 0.54
GRIK2 Q13002 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5089980 0.86 GRIK1 (0.52) SLC1A1GSRGRM8GRM6GRM7
SCHEMBL435289 0.84 SLC1A1 (0.34) SLC1A1GSRGRM8GRM6GRM7
SCHEMBL5053704 0.82 SLC1A1 (0.34) SLC1A1GSRGRM8GRM6GRM7
SCHEMBL3734634 0.79 BLM (0.32) SLC1A1GSRGRM8GRM6GRM7
SCHEMBL3196025 0.79 GRIK1 (0.48) SLC1A1GRIK1GRIA1GRIA2GRIA4
SCHEMBL28196876 0.79 GRIK1 (0.48) SLC1A1GRIK1GRIA1GRIA2GRIA4
SCHEMBL10932186 0.79 SLC1A1 (0.62) SLC1A1GSRGRM8GRM6GRM7
SCHEMBL21777206 0.78 GRM8 (0.31) SLC1A1GSRGRM8GRM6GRM7
SCHEMBL25430984 0.77 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRM7
SCHEMBL23303349 0.77 SLC1A1 (0.50) SLC1A1GSRGRM8GRM6GRM7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124863-A1 EVOLUTION OF PROTEASES PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-04-18 US disclosed
WO-2024050007-A1 GTP CYCLOHYDROLASE-CLEAVING PROTEASES THE BROAD INSTITUTE, INC. (US) 2024-03-07 WO disclosed
US-11912664-B2 Determining small molecule-protein and protein-protein interactions PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-02-27 US disclosed
WO-2024038447-A1 CHIMERIC CASEIN AND WHEY PROTEINS AND USE THEREOF IMAGINDAIRY LTD. (IL) 2024-02-22 WO disclosed
US-20240052331-A1 EVOLUTION OF BOTULINUM NEUROTOXIN PROTEASES THE BOARD INSTITUTE, INC. (US) 2024-02-15 US disclosed
WO-2024003418-A1 IMPROVED DOWNREGULATION OF HISTONE CYTOTOXICITY BY COMPLEX OF NEGATIVELY CHARGED POLYSACCHARIDE AND PROTEASE UNIVERSITEIT MAASTRICHT (NL) 2024-01-04 WO disclosed
US-20230365624-A1 NOVEL ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES THAI UNION GROUP PUBLIC CO LTD (TH) 2023-11-16 US disclosed
CN-114045319-B Control of restriction enzyme activity using proteases 武汉爱博泰克生物科技有限公司 2023-10-17 CN disclosed
EP-4256070-A1 NOVEL ANGIOTENSIN I-CONVERTING ENZYME (ACE) INHIBITORY PEPTIDES Thai Union Group Public Company Limited (TH) 2023-10-11 EP disclosed
US-11781126-B2 Using proteases to control star activity of restriction enzymes ABCLONAL SCIENCE, INC. (US) 2023-10-10 US disclosed
WO-2015179402-A1 METHODS OF FOLDING A GRAFT COPOLYMER WITH DUAL ANTICANCER DRUGS AND RELATED APPLICATIONS NORTH CAROLINA STATE UNIVERSITY (US) 2015-11-26 WO disclosed
US-20150290362-A1 HYBRID FIBRIN-MICROGEL CONSTRUCTS FOR TISSUE REPAIR AND REGENERATION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-15 US disclosed
US-20140079638-A1 NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES Fundacion de la Comunidad Valenciana Centro de Investigacion Principle Felipe (ES) 2014-03-20 US disclosed
US-8586019-B2 Conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2013-11-19 US disclosed
US-20110286923-A1 NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES Fundacion de la Communidad Valenciana Centro de Investigacion principe felipe (ES) 2011-11-24 US disclosed
CN-102105156-A Novel conjugates of polymers having attached therapeutically active agents and angiogenesis targeting moieties and their use in treating angiogenesis-related diseases UNIV RAMOT 2011-06-22 CN disclosed
US-20110091577-A1 DRUG RELEASE COATINGS ON CALCUIM PHOSPHATE AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. 2011-04-21 US disclosed
EP-2307032-A2 NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES Ramot at Tel-Aviv University Ltd. (IL) 2011-04-13 EP disclosed
WO-2009141826-A2 NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2009-11-26 WO disclosed
WO-2009131638-A2 DRUG RELEASE COASTINGS ON CALCIUM PHOSPHATE AND USES THEREOF YESHIVA UNIVERSITY (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140079638-A1 NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES VEGFA, FLT4, FLT1 SLC1A1 3753/4885GSR 2462/4885GRM8 3577/4885
US-20110286923-A1 NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES VEGFA, FLT4, FLT1 SLC1A1 3753/4885GSR 2462/4885GRM8 3577/4885
US-11912664-B2 Determining small molecule-protein and protein-protein interactions MAX, IK, CRYAA SLC1A1 2638/4885GSR 4628/4885GRM8 3099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.